DLL4 expression is a prognostic marker and may predict gemcitabine benefit in resected pancreatic cancer.

Last updated on 15-12-2020 by Annabelle Calomme

Public Access


Peer reviewed scientific article



BACKGROUND: There is an increasing interest for Notch signalling pathway and particularly Delta-like ligand 4 (DLL4) as potential therapeutic target to improve outcome for patients with pancreatic ductal adenocarcinoma (PDAC). METHODS: Using immunohistochemistry (IHC) and tissue microarray (TMA), we assessed the expression patterns of DLL4, Notch1 and Notch3 in 151 patients from two independent cohorts of resected PDAC. We investigated the prognostic and the predictive significance of these proteins. RESULTS: High IHC DLL4 expression in cancer cells was associated with worse overall s…

Associated health topics:

QR code

QR code for this page URL